Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Jan 19, 2022 4:30pm
143 Views
Post# 34334734

RE:RE:RE:RE:RE:RE:Streetwise Reports:

RE:RE:RE:RE:RE:RE:Streetwise Reports:That would have been a good question to ask the CEO at the Q&A yetserday. The buck stops with the CEO IF THEY BELIEVE something nefarious is taking place with stock manipulation. Former Algernon - Breathtec Biomedical was investigated by IIROC and did expose a group of orgainzed manipulators/crooks. Whether anyone went to jail behind it, who knows? What I do know is the stock and the narrative still remains under the thumb of CSE/OTC flippers. Much bigger news has yet to unfold. For starters, Nasdaq uplist and start of the DMT-Stroke clinical trial. Neither has happened yet. Meanwhile, we have news boys and news girls selling their papers. It's not like today's news was not already telegraphed by the CEO in the Q&A two days ago. The setup to flip was there given the timeline the CEO put out thereforf Nasdaq being a 3 month application decision window and the DMT clinical trial likely starting around the same time as the uplist IF all goes according to plan. The stock traded j2% of the total outstanding shares today. That's not a mass exodus of shareholders. To directly answer your question. How do you expect us to know? Doesn't that type of thing remain secret unless and until there's some there there?
<< Previous
Bullboard Posts
Next >>